Cargando…

Incorporation of high-dose (131)I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study

BACKGROUND: In our previous SMC NB-2004 study of patients with high-risk neuroblastomas, which incorporated total-body irradiation (TBI) with second high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT), the survival rate was encouraging; however, short- and long-term toxic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ji Won, Lee, Sanghoon, Cho, Hee Won, Ma, Youngeun, Yoo, Keon Hee, Sung, Ki Woong, Koo, Hong Hoe, Cho, Eun Joo, Lee, Suk-Koo, Lim, Do Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432997/ https://www.ncbi.nlm.nih.gov/pubmed/28511709 http://dx.doi.org/10.1186/s13045-017-0477-0

Ejemplares similares

Iron Overload during Follow-up after Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma
por: Bae, Soo Jin, et al.
Publicado: (2012)

Tandem High-dose Chemotherapy without Craniospinal Irradiation in Treatment of Non-metastatic Malignant Brain Tumors in Very Young Children
por: Ma, Youngeun, et al.
Publicado: (2020)

Promising survival rate but high incidence of treatment‐related mortality after reduced‐dose craniospinal radiotherapy and tandem high‐dose chemotherapy in patients with high‐risk medulloblastoma
por: Lee, Ji Won, et al.
Publicado: (2020)

MBCL-28. LONG-TERM FOLLOW-UP RESULTS OF REDUCED DOSE CRANIOSPINAL RADIOTHERAPY AND TANDEM HIGH-DOSE CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK MEDULLOBLASTOMA
por: Lee, Ji Won, et al.
Publicado: (2020)

Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Grade Gliomas in Children and Adolescents
por: Lee, Ji Won, et al.
Publicado: (2017)

Double high-dose chemotherapy with autologous stem cell transplantation in patients with high-risk neuroblastoma: a pilot study in a single center.
por: Sung, Ki Woong, et al.
Publicado: (2002)

Hematologic Recovery after Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Children with High-Risk Solid Tumors
por: Son, Meong Hi, et al.
Publicado: (2013)

High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients with High-risk Stage 3 Neuroblastoma: 10-Year Experience at a Single Center
por: Suh, Jung Min, et al.
Publicado: (2009)

Infectious Complications during Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Children with High-Risk or Recurrent Solid Tumors
por: Choi, Young Bae, et al.
Publicado: (2016)

Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol
por: Araki, Raita, et al.
Publicado: (2018)

Metastatic Burden Defines Clinically and Biologically Distinct Subgroups of Stage 4 High-Risk Neuroblastoma
por: Seo, Eun Seop, et al.
Publicado: (2020)

Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Atypical Teratoid/Rhabdoid Tumor
por: Sung, Ki Woong, et al.
Publicado: (2016)

High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Children with High-Risk or Recurrent Bone and Soft Tissue Sarcomas
por: Choi, Young Bae, et al.
Publicado: (2016)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective
por: Kayano, Daiki, et al.
Publicado: (2015)

Treatment Outcomes in Children and Adolescents with Relapsed or Progressed Solid Tumors: a 20-year, Single-Center Study
por: Cho, Hee Won, et al.
Publicado: (2018)

The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis
por: He, Huihui, et al.
Publicado: (2022)

(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
por: Garaventa, A, et al.
Publicado: (1999)

Efficacy of Tandem High-Dose Chemotherapy and Autologous Stem Cell Rescue in Patients Over 1 Year of Age with Stage 4 Neuroblastoma: The Korean Society of Pediatric Hematology-Oncology Experience Over 6 Years (2000-2005)
por: Sung, Ki Woong, et al.
Publicado: (2010)

Clinical significance of germline telomere length and associated genetic factors in patients with neuroblastoma
por: Bae, Joon Seol, et al.
Publicado: (2022)

I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma
por: Sato, Yuya, et al.
Publicado: (2012)

Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
por: Bleeker, Gitta, et al.
Publicado: (2013)

Clinical Significance of Persistent Tumor in Bone Marrow during Treatment of High-risk Neuroblastoma
por: Choi, Young Bae, et al.
Publicado: (2015)

Clinical Significance of Segmental Chromosomal Aberrations in Patients with Neuroblastoma: First Report in Korean Population
por: Lim, Hana, et al.
Publicado: (2020)

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma
por: Lee, Eunjin, et al.
Publicado: (2020)

Differential Clinical Significance of Neurotrophin-3 Expression according to MYCN Amplification and TrkC Expression in Neuroblastoma
por: Seo, Eunseop, et al.
Publicado: (2019)

Safety and immune cell kinetics after donor natural killer cell infusion following haploidentical stem cell transplantation in children with recurrent neuroblastoma
por: Choi, Young Bae, et al.
Publicado: (2019)

Absolute Neutrophil Count after the First Chemotherapy Cycle as a Surrogate Marker for Treatment Outcomes in Patients with Neuroblastoma
por: Lee, Ji Won, et al.
Publicado: (2022)

Induction Regimen in High-Risk Neuroblastoma: A Pilot Study of Highly Effective Continuous Exposure of Tumor Cells to Radio-Chemotherapy Sequence for 1 Month. The Critical Role of Iodine-131-Metaiodobenzylguanidine
por: Mastrangelo, Stefano, et al.
Publicado: (2022)

Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma
por: Kim, Chiwoo, et al.
Publicado: (2018)

Neuroblastoma Originating from Extra-abdominal Sites: Association with Favorable Clinical and Biological Features
por: Sung, Ki Woong, et al.
Publicado: (2009)

Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma
por: Lee, Na Hee, et al.
Publicado: (2016)

Reduced-dose craniospinal radiotherapy followed by high-dose chemotherapy and autologous stem cell rescue for children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuroectodermal tumor
por: Kim, Sun Young, et al.
Publicado: (2010)

Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors
por: Lee, Ji Won, et al.
Publicado: (2019)

Development of a porcine skin injury model and characterization of the dose-dependent response to high-dose radiation
por: Kim, Jun Won, et al.
Publicado: (2013)

Optimal Time to Start Peripheral Blood Stem Cell Collection in Children with High-Risk Solid Tumors
por: Sung, Ki Woong, et al.
Publicado: (2014)

DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes
por: Ju, Hee Young, et al.
Publicado: (2021)

OR29-3 High-specific-activity Iodine 131 Metaiodobenzylguanidine for the Treatment of Advanced Pheochromocytoma and Paraganglioma: A Real-world Study
por: Al-ward, Ruaa
Publicado: (2022)

Etoposide sensitizes neuroblastoma cells expressing caspase 8 to TRAIL
por: Kim, Hye Ryung, et al.
Publicado: (2012)

Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours
por: Nwosu, A C, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_2c2uddp41epsh3l21uacrj5gqn